
Bioventus (BVS) Stock Forecast & Price Target
Bioventus (BVS) Analyst Ratings
Bulls say
Bioventus is showing a consistent growth trajectory, as evidenced by its strong Q4 result and better-than-expected financial guidance. This growth is expected to continue with a strong focus on its pain treatments and surgical solutions businesses, as well as investments in emerging areas such as peripheral nerve stimulation and platelet-rich plasma. The company's solid profit margins and focus on debt reduction also make it a financially stable investment option. With an optimistic outlook, Bioventus's stock appears to be a promising investment for the future.
Bears say
Bioventus is facing heavy investment in its growth drivers (PNS, PRP, ultrasonics, and international) in 2026, and it remains unclear how much success the company will have in building its PNS business. While their pain treatments business showed strong growth in the last quarter, it is uncertain if the company can maintain this level of growth and profitability without significant investments. Recent contract wins, an extra selling day, and favorable order timing may have contributed to the exceptional results in the quarter.
This aggregate rating is based on analysts' research of Bioventus and is not a guaranteed prediction by Public.com or investment advice.
Bioventus (BVS) Analyst Forecast & Price Prediction
Start investing in Bioventus (BVS)
Order type
Buy in
Order amount
Est. shares
0 shares